HomeComparePSGCX vs ABBV

PSGCX vs ABBV: Dividend Comparison 2026

PSGCX yields 91.69% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSGCX wins by $20998013420264.00M in total portfolio value
10 years
PSGCX
PSGCX
● Live price
91.69%
Share price
$9.04
Annual div
$8.29
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20998013420264.11M
Annual income
$20,954,109,247,320,396,000.00
Full PSGCX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PSGCX vs ABBV

📍 PSGCX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSGCXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSGCX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSGCX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSGCX
Annual income on $10K today (after 15% tax)
$7,793.28/yr
After 10yr DRIP, annual income (after tax)
$17,810,992,860,222,335,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, PSGCX beats the other by $17,810,992,860,222,314,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSGCX + ABBV for your $10,000?

PSGCX: 50%ABBV: 50%
100% ABBV50/50100% PSGCX
Portfolio after 10yr
$10499006710132.11M
Annual income
$10,477,054,623,660,210,000.00/yr
Blended yield
99.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PSGCX
No analyst data
Altman Z
4.7
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSGCX buys
0
ABBV buys
0
No recent congressional trades found for PSGCX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSGCXABBV
Forward yield91.69%3.06%
Annual dividend / share$8.29$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$20998013420264.11M$102.3K
Annual income after 10y$20,954,109,247,320,396,000.00$24,771.77
Total dividends collected$20995130640805.15M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PSGCX vs ABBV ($10,000, DRIP)

YearPSGCX PortfolioPSGCX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$29,037$18,337.12$11,550$430.00+$17.5KPSGCX
2$130,594$99,524.74$13,472$627.96+$117.1KPSGCX
3$976,395$836,658.84$15,906$926.08+$960.5KPSGCX
4$12,736,920$11,692,176.99$19,071$1,382.55+$12.72MPSGCX
5$298,717,528$285,089,023.82$23,302$2,095.81+$298.69MPSGCX
6$12,817,124,015$12,497,496,260.30$29,150$3,237.93+$12817.09MPSGCX
7$1,016,017,515,076$1,002,303,192,380.15$37,536$5,121.41+$1016017.48MPSGCX
8$149,597,221,440,248$148,510,082,699,116.60$50,079$8,338.38+$149597221.39MPSGCX
9$41,031,937,330,568,370$40,871,868,303,627,300.00$69,753$14,065.80+$41031937330.50MPSGCX
10$20,998,013,420,264,110,000$20,954,109,247,320,396,000.00$102,337$24,771.77+$20998013420264.00MPSGCX

PSGCX vs ABBV: Complete Analysis 2026

PSGCXStock

The investment seeks long-term capital appreciation. Under normal circumstances, the fund invests at least 80% of its assets in common stocks of small market capitalization companies. It pursues long-term capital appreciation in the small capitalization market while seeking to incur less risk than the small capitalization growth market. The fund invests in a select group of small market capitalization companies believed by the fund&#39;s subadviser to possess sustainable competitive advantages at prices the subadviser deems attractive.

Full PSGCX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PSGCX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSGCX vs SCHDPSGCX vs JEPIPSGCX vs OPSGCX vs KOPSGCX vs MAINPSGCX vs JNJPSGCX vs MRKPSGCX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.